Background In a pilot study involving patients with cutaneous squamous-cell carcinoma, a
high percentage of patients had a pathological complete response with the use of two doses …

Background Cemiplimab has shown substantial antitumour activity in patients with
metastatic cutaneous squamous cell carcinoma. Patients with locally advanced cutaneous …

Simple Summary Prognosis of advanced cutaneous squamous-cell carcinoma (CSCC) is
poor. Recent clinical trials have shown that immunotherapy achieves significantly improved …

10018 Background: Cemiplimab monotherapy achieves clinically meaningful activity in pts
with advanced CSCC (metastatic [mCSCC] or locally advanced [laCSCC] not amenable to …

Aim: To estimate the comparative efficacy of cemiplimab, a programmed cell death protein 1
inhibitor, versus EGFR inhibitors, pembrolizumab and platinum-based chemotherapy in …

Background Cutaneous squamous cell carcinoma (cSCC) has an overall favourable
outcome, except for patients with an advanced stage disease. The programmed death …

Cemiplimab (Libtayo®) is an antibody immunotherapy that stimulates an anti-cancer
response via programmed cell death protein-1 (PD-1) blockade. It is the first approved …

Prior studies of conventional chemotherapy or epidermal growth factor receptor inhibitors for
advanced (ie, locally advanced cutaneous squamous cell carcinoma [laCSCC] or metastatic …

In order to update recommendations on treatment, supportive care, education, and follow-up
of patients with invasive cutaneous squamous cell carcinoma (cSCC), a multidisciplinary …

Background No systemic therapies have been approved for the treatment of advanced
cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy …